

Antigenic Modulation and Rituximab Resistance

Ronald P. Taylor and Margaret A. Lindorfer

Several types of B-cell lymphoma have been successfully treated with rituximab, and approval by the US Food and Drug Administration for use of rituximab in the treatment of rheumatoid arthritis has increased interest in targeting CD20 on B cells for other indications. Although large amounts of rituximab can be infused into humans with no apparent dose-limiting toxicity, recent evidence suggests that the body's effector mechanisms, including complement-mediated cytotoxicity and natural killer (NK) cell-mediated killing, can be saturated or exhausted at high burdens of rituximab-opsonized B cells. One of the consequences of this saturation phenomenon is that the opsonized B cells are instead processed by a different pathway mediated by Fc γ R on effector cells. In this alternative pathway, both rituximab and CD20 are removed ("shaved") from the B cells and are taken up by monocytes/macrophages. This process, formerly called antigenic modulation, appears to occur in several compartments in the body and may play a key role in the development of resistance to rituximab therapy.

Semin Hematol 47:124–132. © 2010 Elsevier Inc. All rights reserved.

The mechanisms of B-cell resistance to rituximab-mediated cytotoxicity, can, like much of immunology, be divided into innate and adaptive components. Innate components include expression of CD20 at levels below the thresholds required to trigger rituximab-mediated cytotoxicity, and the activity and level of complement control proteins on malignant cells.^{1–4} A patient's innate cytotoxic effector mechanisms will play critical roles, as demonstrated by differences in efficacy that correlate with polymorphisms in C1q and polymorphisms in and effector cell densities of Fc γ R.^{5–9} In addition, as noted by Smith,¹⁰ differences in resistance of cells in different compartments "could reflect differential access to antibody or to effector mechanisms," emphasizing the importance of tumor microenvironments.

Treatment with rituximab does not destroy all malignant B cells, and over the long term (periods in excess of 1 year) surviving B cells appear to acquire an adaptive resistance to later rituximab therapies,^{11,12} although in many cases the malignant cells still express CD20. The surviving cells may take up residence in compartments in which they will be resistant to later attack by rituximab, but there is no evidence for or

against this possibility. Over the short term, that is, at the time of rituximab treatment, there are several adaptive mechanisms by which targeted cells can escape rituximab-mediated cytotoxicity. As noted below, deposition of C3 activation fragments on rituximab-opsonized cells can block binding to Fc γ RIIIa on natural killer (NK) cells, inhibiting antibody-dependent cellular cytotoxicity (ADCC).¹³ Although not yet formally proven for rituximab, there is evidence that sublytic complement attack on nucleated cells induces Ca²⁺ fluxes, leading to protein synthesis and at least temporary upregulation of defenses against complement-dependent cytotoxicity (CDC).¹⁴ Rituximab treatment may acutely exhaust effector mechanisms responsible for killing IgG-opsonized substrates. Under these conditions, an alternative processing pathway that removes rituximab/CD20 complexes from B cells predominates, thus insuring the resistance of CD20-negative cells to rituximab therapy. **Table 1** summarizes some of the mechanisms by which resistance to rituximab develops and also presents potential therapeutic strategies to overcome this resistance. In this review we will focus our discussion on the loss of efficacy of rituximab treatment due to blockade or saturation of host effector mechanisms.

CYTOTOXIC MECHANISMS: VARIATIONS ON IMMUNE COMPLEX PROCESSING

Seven years ago our laboratory initiated a clinical study in chronic lymphocytic leukemia (CLL) to determine whether infusion of rituximab promotes complement activation and deposition of C3 activation fragments

Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA.

Address correspondence to Ronald P. Taylor, PhD, Department of Biochemistry and Molecular Genetics, PO Box 800733, University of Virginia, Charlottesville, VA 22908. E-mail: rpt@virginia.edu

0037-1963/10/\$ - see front matter

© 2010 Elsevier Inc. All rights reserved.

doi:10.1053/j.seminhematol.2010.01.006

Table 1. Mechanisms of Resistance to Rituximab Therapy and Potential Therapeutic Strategies to Overcome Resistance

Mechanism	Potential Therapeutic Strategies	References
● Loss of epitope		
Permanent loss of CD20 (ie, outgrowth of a CD20-negative clone)	Target alternative epitope (eg, CD52)	11,64
Temporary mAb-mediated loss of CD20 (ie, shaving)	Lower, more frequent doses of mAb; intravenous immunoglobulin or other agents to block Fc γ RI	15,17,62,72
● Reduced ADCC		
Exhaustion of ADCC	Lower, more frequent doses of mAb; increase activity or number of NK cells	39–41,46,47
Blockade of ADCC by deposited C3 activation fragments	Engineer mAbs, or adjust the dose in order to maximize ADCC while minimizing C3 fragment deposition	13,32
Polymorphisms in effector molecules (ie, Fc γ R)	Screen polymorphisms prior to therapy; engineer Fc region of mAbs to maximize ADCC for all patients	5–7,43–45
● Reduced CDC		
Increased surface expression of complement control proteins	Block the action of CD55 or CD59	73
Exhaustion of CDC (ie, temporary depletion of complement components)	Infusion of fresh frozen plasma; lower, more frequent doses of mAb	15,17,52
Sublytic C attack leading to increased resistance to CDC	mAb designed to maximize C activation and thereby minimize sublytic C attack	14,33,35
● Tumor microenvironment		
Protective factors in tumor microenvironment	Mobilize malignant cells to periphery; attack stromal factors	74–76

on circulating CLL B cells.¹⁵ We had demonstrated that *in vitro* binding of rituximab to B cells in the presence of complement leads to deposition of C3 fragments on the cells; our findings in primates indicated that within minutes of rituximab infusion, C3 fragments were deposited on rituximab-opsonized cells.^{3,16} In both cases, C3b/iC3b was co-localized with cell-bound rituximab. In the clinical study, we found that after infusion of only 30 mg of rituximab, C3 fragments were demonstrable on circulating B cells. However, an unexpected observation set the stage for future investigations: the number of circulating CLL B cells decreased considerably after infusion of 30 mg but then substantially increased after infusion of the remaining ~600 mg rituximab (~5 hours later). Although the final concentration of rituximab in the bloodstream (>100 μ g/mL) was considerably higher than the concentration after infusion of the first 30 mg (<5 μ g/mL), it appeared that the cytotoxic action of rituximab had been saturated or exhausted; that is, B cells were not cleared from the bloodstream with a high level of efficacy. This finding has been quite durable (Table 2); we observed this pattern in all of our studies of CLL patients receiving single-agent rituximab therapy in doses of \geq 100 mg.¹⁷

These observations dramatically emphasize the need for detailed analyses of the cytotoxic mechanisms of rituximab in different compartments in the body and in the bloodstream in particular.

An overwhelming body of evidence indicates that rituximab-mediated cytotoxicity must rely on the body's immune mechanisms.^{1–3,9,15,18–23} These cytotoxic reactions are initiated by recognition of the rituximab/CD20/B-cell immune complex, either by Fc γ R on effector cells (NK cells and monocyte/macrophages) or by C1q, the first component of the classical pathway of complement. Recognition of IgG-opsonized substrate cells by Fc γ RIIIa on NK cells can promote ADCC.^{18,24,25} IgG-opsonized cells can also bind to macrophages via several different Fc γ R, setting in motion cytotoxic pathways that lead to ADCC and phagocytosis.^{19,26} The classic studies of Schreiber and Frank, which examined bloodstream clearance mechanisms mediated by the mononuclear phagocytic system (MPS), revealed that binding of a few thousand IgG molecules to a circulating cell such as an erythrocyte leads to its rapid clearance due to recognition by Fc γ R on tissue macrophages in the liver (Kupffer cells) and spleen.^{26,27} Studies of polymorphisms in CD16 (Fc γ RIIIa),

Table 2. Key Measurements on CLL Blood Samples, Before, During, and After Rituximab Infusion

	Before Treatment	After 30 mg	After 375 mg/m ²
Normalized lymphocyte count	High* 100%	Low 20%	Intermediate 60%
Plasma rituximab concentration	0	1–5 µg/mL	>100 µg/mL
Total hemolytic complement titer	Normal	Normal	Depleted (10%–90%)
CD20/cell, normalized	100	2–10	2–10
C3 fragments deposited	No	Yes	Yes

*Pretreatments levels varied from 5,000–100,000 lymphocytes/µL.^{15,17}

first reported by Cartron et al and confirmed by others,^{5–7} indicate that individuals homozygous for the higher affinity binding FcγRIIIa allotype (158 valine) have considerably better responses to rituximab therapy. This result underlines the importance of ADCC and phagocytosis in the rituximab mechanism.

IgG-opsonized cells can bind C1q, promoting several consecutive steps in the classical complement activation pathway, including covalent deposition of C3 activation fragments on the cells, followed by CDC due to assembly and penetration of the cell membrane by numerous copies of the cytolytic membrane attack complex (MAC).²³ Rituximab can mediate CDC of B cells that express high levels of CD20. The results in certain mouse models,^{28,29} as well as the report of Racila et al,⁸ which correlated the response of patients with follicular lymphoma to polymorphisms in C1q, all suggest that CDC may play a role in the therapeutic action of rituximab. However, primary B cells from most CLL patients are refractory to rituximab-mediated CDC due to relatively low levels of expression of CD20. Upon infusion of rituximab, circulating CLL cells that are not lysed become heavily opsonized with C3 fragments^{3,17}; these C3 fragments may promote clearance of the opsonized cells by the MPS, due to uptake mediated by complement receptors on fixed cells.^{30,31} Conversely, several lines of evidence developed by Weiner and colleagues suggest that C3 fragments bound to rituximab-opsonized B cells may actually interfere with NK cell-promoted ADCC due to C3b/iC3b-mediated blockade of access of NK cell CD16 to the Fc region of cell-bound rituximab.^{13,32} Thus, it will be important to determine the relative impact of C3 fragment deposition in targeting rituximab-opsonized circulating cells to the MPS compared to the effect of complement activation on sessile, noncirculating cells in tumors.

These potential problems may be overcome with second-generation anti-CD20 monoclonal antibodies (mAbs) such as ofatumumab. Ofatumumab mediates CDC of B cells more effectively than rituximab, most likely due to increased binding of C1q to opsonized cells.³³ Indeed, ofatumumab makes much more effi-

cient use of complement than does rituximab and can, in the presence of limited amounts of complement, mediate much higher levels of C3b deposition and CDC than does rituximab in the presence of much larger amounts of complement.^{33–35} Based on these observations, treatment of patients with high B-cell burdens with rituximab is more likely to consume complement due to inefficient cell killing compared to treatment with comparable amounts of ofatumumab, and future clinical studies should allow for evaluation of this prediction.

SATURATION AND/OR EXHAUSTION

A key question is whether the body's effector mechanisms associated with immune complex processing, complement activation, phagocytosis, and/or ADCC can be saturated or exhausted, leading to persistence and proliferation of malignant B cells that would otherwise be eliminated. That is, the B-cell burden may be so high that although large doses of rituximab saturate CD20 on targeted B cells in different body compartments, the necessary effector mechanisms within these compartments are not adequate to effectively kill targeted cells.

Insight into this question may be drawn from studies in systemic lupus erythematosus (SLE). SLE is an autoimmune disease characterized by chronic proliferation of large quantities of immune complexes in the circulation and in tissues.^{36–38} The kinetics of clearance from the circulation of a model particulate immune complex, chromium 51-labeled IgG-opsonized erythrocytes, are reduced substantially in SLE, likely due to competition by circulating immune complexes.³⁶ These IgG-containing complexes can bind to FcγR on monocytes/macrophages, and then the immune complexes, along with FcγR, are internalized. This process appears to down-modulate expression of FcγRII and FcγRIII, compromising the activity of monocyte/macrophages in clearing IgG-opsonized particles.³⁸

In another example of saturation and exhaustion, Bowles and Weiner reported that NK cell-mediated ADCC of rituximab-opsonized cells comes at a price, in

that CD16 (Fc γ RIIIa) on the NK cells is severely down-regulated.³⁹ The consequence of down-regulation is inhibition of killing of additional rituximab-opsonized B cells until CD16 can be re-expressed. In vitro experiments reported by Bhat and Watzl suggest that one NK cell can kill at most four IgG-opsonized cells.⁴⁰ In vivo findings of Berdeja et al indicate that after NK cell-mediated ADCC, re-expression of CD16 on the NK cell and restoration of full cytotoxic activity may require 24 hours or more.⁴¹ Varchetta et al reported that as a consequence of NK cell-mediated ADCC of trastuzumab-opsonized cells, CD16 on the NK cells is down-modulated, suggesting that NK cell-mediated ADCC of other targets may also be subject to saturation.⁴² In the future, anti-CD20 mAbs with Fc regions engineered to maximize ADCC may provide increased efficacy, and methods to increase NK cell cytotoxicity and/or numbers are under development.⁴³⁻⁴⁷

Treatment of immune thrombocytopenia (ITP) with IgG anti-erythrocyte antibodies (anti-D) makes explicit use of saturation of effector mechanisms.⁴⁸ This treatment leads to modest decreases in the hematocrit due to clearance of IgG-opsonized erythrocytes; however, the decoy IgG-erythrocyte immune complexes saturate the clearance capacity of the MPS, sparing IgG-opsonized platelets and providing effective therapy for certain patients.⁴⁹ Part of this saturation phenomenon is likely due to down-modulation of Fc γ RIII. Song et al examined a mouse model for this system and reported that as a result of targeting erythrocytes by infusion of specific IgG antibodies, splenic Fc γ RIII was down-modulated.⁵⁰ It is likely that splenic Fc γ RIII was internalized coincident with phagocytosis of IgG-opsonized erythrocytes.

The complement system can be exhausted as a consequence of rituximab treatment. Rituximab-opsonized B cells at densities seen in CLL (100,000 B cells per μ L) substantially depleted complement activity in serum.¹⁵ Although the cells were saturated with bound rituximab, CDC was reduced considerably compared to CDC seen for lower cell burdens, where complement activity was adequate. The first CLL patient we studied had a moderate burden of circulating B cells (< 20,000 per μ L), yet rituximab treatment led to massive depletion of complement immediately after the first infusion.¹⁵ His complement titer was partially restored 1 week later, but after the second weekly rituximab treatment (in a 4-week cycle) complement remained low for more than a month, suggesting that the rituximab-B cell immune complexes, in several compartments in addition to the bloodstream, were continuing to activate and deplete complement. Complement titers were decreased in other CLL patients who received rituximab therapy; the time for restoration of full complement activity after rituximab treatment was variable, from days to weeks.¹⁵ Therefore we suggested that fresh frozen plasma as a complement source may en-

hance rituximab therapeutic activity,^{15,51} and recent clinical studies, although not well controlled, have provided some evidence in favor of this paradigm.⁵² However, infusion of 2 units of fresh frozen plasma may not be adequate to provide substantial long-term restoration of complement titers, and additional studies will be required to determine if this approach has therapeutic utility.⁵²

EXHAUSTION CAN RESULT IN INCREASED RESISTANCE: SHAVING

High levels of rituximab-opsonized B cells can saturate effector mechanisms that would otherwise promote rituximab-mediated cytotoxicity. Under these conditions the rituximab/CD20 complexes on B cells will be subject to an alternative processing pathway, the "shaving reaction."^{25,53} In this process rituximab and CD20 are removed from opsonized cells in a reaction mediated by Fc γ R on acceptor cells, but the cells are not killed. This phenomenon was originally described in other systems as antigenic modulation: loss of expression of surface antigens after binding of antibody.^{54,55} Loss of the target of infused mAb T101 (CD5) on circulating malignant T cells was reported by Bertram et al more than 20 years ago.⁵⁴ The shaving reaction resembles trogocytosis (from the Greek, to gnaw or nibble), in which formation of an immunological synapse leads to removal and internalization of ligands associated with donor cells by cognate receptors on acceptor cells. Trogocytosis has been documented for B cells, T cells, neutrophils, and NK cells.⁵⁶

By definition, macrophages are "big eaters" and might not be expected to engage in trogocytosis. However, macrophages can make use of Fc γ R, especially Fc γ RI, to endocytose small IgG-opsonized substrates by taking them into the cell without surrounding them.⁵⁷⁻⁵⁹ Therefore macrophages and other cells that express Fc γ R may be capable of either wholesale phagocytosis and/or ADCC (most likely mediated by Fc γ RII and Fc γ RIII³⁸), or trogocytosis, in which the target cell-bound rituximab (the ligand for Fc γ R) and CD20 are removed and internalized by the acceptor monocyte/macrophage, but the target cell is left alive and intact.⁵⁶ Our investigations of low-dose rituximab for treatment of CLL (see below) suggest that phagocytosis and shaving of rituximab-opsonized B cells occur simultaneously. That is, some rituximab-opsonized cells that enter the liver are effectively bound to Kupffer cells and phagocytosed. However, other rituximab-opsonized cells may pass through the gauntlet of Kupffer cells and escape with some loss of bound rituximab and CD20. We have recently obtained additional evidence that macrophages can mediate either shaving or phagocytosis. After rituximab-opsonized CD20-positive mouse 38C13 B cells²⁹ were incubated with adherent mouse peritoneal macrophages, the cells

were separated and examined. Macrophages had either phagocytosed entire cells, or had trogocytosed small amounts of rituximab and plasma membrane from the B cells. Moreover, the recovered B cells had lost CD20 (Daubeuf et al, *J Immunol*, in press, 2010).

The effector cell phenotype may influence the outcome of an encounter with a target cell. THP-1 cells and freshly isolated monocytes promote shaving of rituximab-opsonized B cells, but do not mediate ADCC or phagocytosis.⁵³ On the other hand, NK cells promote ADCC of rituximab-opsonized cells, and also take up rituximab and CD20 from the cells.²⁵ This process will lead to down-regulation of NK cell CD16, thus suppressing/exhausting its ability to execute ADCC.³⁹ Neutrophils, which express several Fc γ R, also mediate shaving of rituximab-opsonized cells, but in the absence of complement activation and/or other mediators, they do not kill the cells.²⁵

It is an oversimplification to assign all phagocytosis/ADCC to Fc γ RII and Fc γ RIII, and all trogocytosis to Fc γ RI. However, we suggest this provides a reasonable paradigm to explain the transition from clearance and destruction of rituximab-opsonized cells to shaving that occurs when CLL patients with high burdens of circulating cells are treated with standard doses of rituximab (Table 2). The large burden of B cells cleared from the circulation ($\sim 2 \times 10^{11}$) after infusion of only 30 mg of rituximab will likely saturate the phagocytic capacity of liver Kupffer cells ($\sim 2 \times 10^{10}$), as well as the ADCC capacity of circulating NK cells ($\sim 1 \times 10^9$) and in many cases complement activity will be reduced.^{9,15,60} After rituximab-opsonized B cells are cleared, CLL B cells will re-equilibrate into the circulation from other compartments,⁶¹ and be opsonized by rituximab. However, based on the SLE immune complex model,³⁸ as well as the ITP model,^{48,50} Fc γ RII and Fc γ RIII on tissue macrophages and Fc γ RIII on NK cells will be substantially reduced, but Fc γ RI on macrophages and monocytes will be available to promote shaving. The result is that cells which enter the circulation after the first round of clearance will not only escape ADCC and phagocytosis by the MPS, but these cells will also have CD20 removed by the shaving reaction. This adaptive resistance may allow them to escape targeting by rituximab and proliferate.

Therefore, we initiated a pilot clinical trial in CLL to evaluate the effects of much lower, more frequent (thrice-weekly) doses of rituximab on the biology of circulating malignant B cells.¹⁷ The testable hypothesis was that at rituximab doses of ~ 35 mg (20 mg/m²), the plasma concentration of rituximab would be quite low (<5 μ g/mL) after the first round of clearance of opsonized cells. As additional CLL cells entered the circulation from other compartments, these B cells would not be opsonized by rituximab, and cell-associated CD20 would be preserved. It would then be possible to target circulating cells with an additional low rituximab dose

2 days later, when the body's effector systems, previously saturated after the first rituximab dose, would have recovered and could then mediate additional clearance of opsonized B cells. In five of six patients who received the 20 -mg/m² dose, CD20 was largely preserved, and in four of six patients additional rituximab infusions continued to promote clearance of malignant cells. This trial tested mechanisms leading to loss of CD20 on CLL B cells, and the low-dose paradigm may not be adequate for targeting B cells that do not re-equilibrate into the bloodstream.¹⁷ However, these results, taken in context with our findings in CLL patients who received rituximab doses >100 mg (60 mg/m²), provide compelling evidence that the body's effector mechanisms responsible for clearing rituximab-opsonized cells can be saturated, thus sparing a population of rituximab-opsonized cells. This phenomenon evolves into a perfect storm: CD20 will be removed from rituximab-opsonized cells, allowing them to proliferate under conditions that support continued shaving of re-expressed CD20. On the basis of these considerations it is not surprising that single-agent rituximab therapy at standard doses has modest efficacy in CLL.¹ Finally, in collaboration with Wiestner and colleagues, we have found that subcutaneous delivery of lower, more frequent doses of rituximab has the potential to be an effective and convenient paradigm for CLL treatment.⁶²

SHAVING OUTSIDE THE BLOODSTREAM

The clinical success of rituximab in non-Hodgkin lymphoma is well-documented, suggesting that rituximab therapy is more effective at killing B cells in tissues than in the bloodstream.^{9,10} However, approximately 50% of patients treated with single-agent rituximab do not respond, and responding patients often suffer relapses 1 to 2 years later. It is therefore important to ask how effective are the body's effector mechanisms in tissue compartments, and, can these mechanisms also be saturated or exhausted?

It is certainly reasonable that CD20-negative B-cell lymphomas can develop long after rituximab therapy, likely due to outgrowth/mutation of a population of CD20-negative cells.⁶³ However, several immunohistochemical investigations have described CD20-negative B cells (positive for CD79a, CD19, and other B-cell markers) that appeared within a few months or even days after completion of rituximab infusions.⁶³⁻⁷¹ Under these conditions, rituximab was likely present in the circulation and tissues. These studies made use of reagents that would reveal CD20 even in the presence of bound rituximab, thus precluding simple steric blockade as an explanation of the findings. In many of these reports, B cells lacking CD20 were demonstrable in tumors of patients with B-cell lymphomas after rituximab treatment.

Rituximab therapy is also used for other indications, including rheumatoid arthritis or to eliminate B cells before kidney transplants.^{70,71} In these investigations B cells were cleared from the bloodstream for long periods. However, in the rheumatoid arthritis study, B cells lacking CD20 were demonstrable in the bone marrow and synovium. In the transplant study, splenectomies were performed 3–13 days after rituximab infusion. B cells that were CD79a-positive but CD20-negative were found in the spleens of patients who received rituximab infusions ≥ 35 mg/m². The results of these two investigations suggest that although bloodstream clearance was effective due to the large capacity of the MPS to clear “normal” levels of opsonized B cells, cytotoxic mechanisms within tissue compartments responsible for eliminating normal B cells may have been exhausted. We suggest that a substantial fraction of the B cells in tissues had lost CD20 due to the shaving reaction. In principle it should be possible to test this hypothesis by sterile culture of isolated B cells for a few days in the absence of rituximab, to allow for CD20 to be re-expressed. Examination of the levels of CD16 on monocyte/macrophages and NK cells within tissue compartments in which shaving is suspected could be quite informative. If CD16 were down-regulated, this would be consistent with the overall working hypothesis we have presented.

CONCLUSIONS AND FUTURE DIRECTIONS

As we have noted in the introduction, there is increasing evidence that long after patients with B-cell lymphomas are successfully treated with rituximab, they suffer relapses and in many cases their disease is refractory to additional rituximab treatments that include chemotherapy, although their B cells do express CD20.^{11,12} The reason(s) for this apparent adaptive rituximab resistance remain unknown, and it is not unreasonable to speculate that one or more of the short-term mechanisms that allow cells to chronically escape rituximab-mediated cytotoxicity may play key roles in this phenomenon. The elucidation of these long-term resistance “pathways” constitutes a significant challenge not only for anti-CD20 therapies but also likely with respect to other mAb-based therapies in the treatment of cancer. Many different approaches for abrogating resistance to immunotherapy are currently under investigation (Table 1).

Our discovery of the shaving reaction (or perhaps rediscovery of antigenic modulation) was based on clinical observations in CLL. Additional clinical studies, as well as in vitro experiments, have provided important new insights into how rituximab-opsonized B cells are either killed by or escape the body’s immune effector mechanisms. Rituximab is now used in combination with a variety of chemotherapeutic regimens, with a higher level of clinical efficacy, and therefore mech-

anisms of resistance will change. However, it is likely that many of the lessons learned in analyzing innate and adaptive mechanisms of resistance of targeted cells to rituximab will be applicable toward understanding the action of other immunotherapeutic mAbs.⁹

ACKNOWLEDGMENT

Work from the authors’ laboratory cited in this review was supported in part by the University of Virginia National Institutes of Health (NIH) Cancer Center Support Grant, an NIH Bench to Bedside Award, the Commonwealth Foundation for Cancer Research, the James and Rebecca Craig Foundation, the Lymphoma Research Foundation, GenMab, and CLL Topics. The authors especially thank C. Venkat and the late P.C. Venkat of CLL Topics for their support.

Financial disclosure: R.P.T. has received research support from GenMab.

REFERENCES

- Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated cell lysis. *Blood*. 2000;95:3900–8.
- Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin’s lymphomas. *Blood*. 2003;101:949–54.
- Kennedy AD, Solga MD, Schuman TA, et al. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. *Blood*. 2003;101:1071–9.
- van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. *Clin Cancer Res*. 2006;12:4027–35.
- Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. *Blood*. 2002;99:754–8.
- Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. *J Clin Oncol*. 2003;21:3940–7.
- Hatjiharissi E, Xu L, Santos DD, et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism. *Blood*. 2007;110:2561–4.
- Racila E, Link BK, Weng WK, et al. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. *Clin Cancer Res*. 2008;14:6697–703.
- Glennie MJ, French R, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. *Mol Immunol*. 2007;44:3823–37.
- Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. *Oncogene*. 2003;22:7359–68.

11. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. *J Clin Oncol*. 2000;18:3135-43.
12. Martin A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. *Haematologica*. 2008;93:1829-36.
13. Wang SY, Racila E, Taylor RP, Weiner GJ. NK cell activation and antibody dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. *Blood*. 2008;111:1456-63.
14. Reiter Y, Ciobotariu A, Jones J, Morgan BP, Fishelson Z. Complement membrane attack complex, perforin, and bacterial exotoxins induce in K562 cells calcium-dependent cross-protection from lysis. *J Immunol*. 1995;155:2203-10.
15. Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. *J Immunol*. 2004;172:3280-8.
16. Beum PV, Lindorfer MA, Hall BE, et al. Quantitative analysis of protein co-localization on B cells opsonized with rituximab and complement using the ImageStream multispectral imaging flow cytometer. *J Immunol Meth*. 2006;317:90-9.
17. Williams ME, Densmore JJ, Pawluczkoysz AW, et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. *J Immunol*. 2006;177:7435-43.
18. Golay J, Manganini M, Facchinetti V, et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. *Haematologica*. 2003;88:1002-12.
19. Lefebvre M-L, Krause SW, Salcedo M, Nardin A. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. *J Immunother*. 2006;29:388-97.
20. Tedder TF, Baras A, Xiu Y. Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. *Springer Semin Immun*. 2006;28:351-64.
21. Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. *Curr Opin Immunol*. 2008;20:444-9.
22. Gong Q, Ou Q, Ye S, et al. Importance of cellular micro-environment and circulatory dynamics in B cell immunotherapy. *J Immunol*. 2005;174:817-26.
23. Walport MJ. Complement. *N Engl J Med*. 2001;344:1058-66.
24. Dall'Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. *Cancer Res*. 2004;64:4664-9.
25. Beum PV, Lindorfer MA, Taylor RP. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. *J Immunol*. 2008;181:2916-24.
26. Schreiber AD, Frank MM. Role of antibody and complement in the immune clearance and destruction of erythrocytes: in vivo effects of IgG and IgM complement fixing sites. *J Clin Invest*. 1972;51:575-82.
27. Kabbash I, Esdaile JM, Henker S, et al. Reticuloendothelial system Fc receptor function in systemic lupus erythematosus: effect of decreased sensitization on clearance of autologous erythrocytes. *J Rheumatol*. 1987;14:487-9.
28. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of Rituximab in vivo. *J Immunol*. 2003;171:1581-7.
29. Golay J, Cittera E, Di Gaetano N, et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. *Haematologica*. 2006;91:176-83.
30. Helmy KY, Katschke KJ, Gorgani NN, et al. CRiG: a macrophage complement receptor required for phagocytosis of circulating pathogens. *Cell*. 2006;124:915-27.
31. Hinglais N, Kazatchkine MD, Mandet C, Appay M, Bariety J. Human liver Kupffer cells express CR1, CR3, and CR4 complement receptor antigens. *Lab Invest*. 1989;61:509-14.
32. Wang SY, Veeramani S, Racila E, et al. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. *Blood*. 2009;114:5322-30.
33. Pawluczkoysz AW, Beurskens FJ, Beum PV, et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or RTX (rituximab): considerably higher levels of CDC are induced by OFA than by rituximab. *J Immunol*. 2009;183:749-58.
34. Taylor RP, Pawluczkoysz AW, Beum PV, et al. Complement activation and complement-mediated killing of B cells promoted by anti-CD20 monoclonal antibodies (mAb) rituximab and ofatumumab are rapid, and ofatumumab kills cells more rapidly and with greater efficacy [abstract]. *Blood*. 2007;118:695a.
35. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin's lymphomas. *Blood*. 2004;104:1793-800.
36. Frank MM, Hamburger MI, Lawley TJ, Kimberly RP, Plotz PH. Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. *N Engl J Med*. 1979;300:518-23.
37. Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. *Annu Rev Immunol*. 2004;22:431-56.
38. Kawai M, Szegedi G. Immune complex clearance by monocytes and macrophages in systemic lupus erythematosus. *Autoimmun Rev*. 2007;6:497-502.
39. Bowles JA, Weiner GJ. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. *J Immunol Methods*. 2005;304:88-99.
40. Bhat R, Watzl C. Serial killing of tumor cells by human natural killer cells: enhancement by therapeutic antibodies. *PLoS ONE*. 2007;2:1-7.
41. Berdeja JG, Hess A, Lucas DM, et al. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells

- improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. *Clin Cancer Res.* 2007;13:2392-9.
42. Varchetta S, Gibelli N, Oliviero B, et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. *Cancer Res.* 2007;67:11991-9.
 43. Bowles JA, Wang S-Y, Link BK, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. *Blood.* 2006;108:2648-54.
 44. de Romeuf C, Dutertre CA, Le Garff-Tavernier M, et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of Fc γ RIIIA/CD16. *Br J Haematol.* 2008;140:635-43.
 45. Stavenhagen JB, Gorlatov S, Tuailon N, et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fc γ receptors. *Cancer Res.* 2007;67:8882-990.
 46. Klingemann HG. Natural killer cell-based immunotherapeutic strategies. *Cytotherapy.* 2005;7:16-22.
 47. Lundqvist A, Yokoyama H, Smith A, Berg M, Childs R. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. *Blood.* 2009;113:6120-7.
 48. Scaradavou A, Woo B, Woloski BMR, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. *Blood.* 1997;89:2689-700.
 49. Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis. *Nat Clin Pract Rheum.* 2007;3:86-95.
 50. Song S, Crow AR, Siragam V, Freedman J, Lazarus AH. Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. *Blood.* 2005;105:1546-8.
 51. Taylor R. Fresh frozen plasma as a complement source. *Lancet Oncol.* 2007;8:370-1.
 52. Klepfish A, Rachmilewitz EA, Kotsianidis I, Patchenko P, Schattner A. Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL. *Q J Med.* 2008;101:737-40.
 53. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. *J Immunol.* 2006;176:2600-9.
 54. Bertram JH, Gill PS, Levine AM, et al. Monoclonal antibody T101 in T cell malignancies: a clinical, pharmacokinetic, and immunologic correlation. *Blood.* 1986;68:752-61.
 55. Schroff RW, Klein RA, Farrell MM, Stevenson HC. Enhancing effects of monocytes on modulation of a lymphocyte membrane antigen. *J Immunol.* 1984;133:2270-7.
 56. Hudrisier D, Aucher A, Puaux AL, Bordier C, Joly E. Capture of target cell membrane components via trogocytosis is triggered by a selected set of surface molecules on T or B cells. *J Immunol.* 2007;178:3637-47.
 57. Guyre C, Keler T, Swink S, et al. Receptor modulation by Fc γ RI-specific fusion proteins is dependent on receptor number and modified by IgG. *J Immunol.* 2001;167:6303-11.
 58. Davis W, Harrison PT, Hutchinson MJ, Allen JM. Two distinct regions of Fc γ RI initiate separate signalling pathways involved in endocytosis and phagocytosis. *EMBO J.* 1995;14:432-41.
 59. Lovdal T, Andersen E, Brech ABT. Fc receptor mediated endocytosis of small soluble immunoglobulin G immune complexes in Kupffer and endothelial cells from rat liver. *J Cell Sci.* 2000;113:3255-66.
 60. Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. *Leukemia.* 2004;18:484-90.
 61. Cooper IA, Ding JC, Adams PB, Quinn MA, Brettell M. Intensive leukapheresis in the management of cytopaenias in patients with chronic lymphocytic leukaemia (CLL) and lymphocytic lymphoma. *Am J Hematol.* 1979;6:387-98.
 62. Aue G, Lindorfer MA, Beum PV, et al. Fractionated subcutaneous rituximab is well tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. *Haematologica.* 2009. E-pub ahead of print. doi:10.3324.
 63. Kennedy GA, Tey SK, Cobcroft R, et al. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. *Br J Haematol.* 2002;119:412-6.
 64. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. *Clin Cancer Res.* 1999;5:611-5.
 65. Foran JM, Norton AJ, Micallef INM, et al. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. *Br J Haematol.* 2001;114:881-3.
 66. Haidar JH, Shamseddine A, Salem Z, et al. Loss of CD20 expression in relapsed lymphomas after rituximab therapy. *Eur J Haematol.* 2003;70:330-2.
 67. Alvaro-Naranjo T, Jaen-Martinez J, Guma-Padro J, et al. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature. *Ann Hematol.* 2003;82:585-8.
 68. Clarke LE, Bayer MG, Ehmann C, Helm KF. Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy. *J Cutan Pathol.* 2003;30:459-62.
 69. Goteri G, Olivieri A, Ranaldi R, et al. Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients' outcome. *Int J Immunopathol Pharmacol.* 2006;19:421-31.
 70. Teng YKO, Levarht EWN, Hashemi M, et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. *Arthritis Rheum.* 2007;56:3909-18.
 71. Toki D, Ishida H, Horita S, Setoguchi K, Yamaguchi Y, Tanabe K. Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients. *Transplant Int.* 2009;22:447-54.

72. Li Y, Williams ME, Cousar JB, Pawluczko-wycz AW, Lindorfer MA, Taylor RP. Rituximab/CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. *J Immunol.* 2007;179:4263-71.
73. Macor P, Tripodo C, Zorzet S, et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. *Cancer Res.* 2007;67:10556-63.
74. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. *Blood.* 2009; 114:3367-75.
75. Mayo Clinic. Everolimus and alemtuzumab in treating patients with recurrent chronic lymphocytic leukemia or small lymphocytic lymphoma. [clinicaltrials.gov NCT00935792](http://clinicaltrials.gov/NCT00935792). 2009.
76. Ghosh AK, Kay NE, Secreto CR, Shanafelt TD. Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. *Clin Cancer Res.* 2009;15:1250-8.